Acceptable toxicity profile is seen with relugolix in advanced prostate cancer

“Relugolix, an oral nonpeptide GnRH receptor antagonist, was generally well tolerated in the phase 3 HERO study,” wrote Bryan Mehlhaff, MD, and coauthors.

Read the full article here

Related Articles